These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3527887)

  • 1. Thrombosis prophylaxis in visceral surgery with the low molecular weight heparin fragment Kabi 2165 (7,500 and 2,500 anti-Xa IU/day).
    Koller M; Schoch U; Buchmann P; Largiadèr F; von Felten A; Frick PG
    Haemostasis; 1986; 16 Suppl 2():69-70. PubMed ID: 3527887
    [No Abstract]   [Full Text] [Related]  

  • 2. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin.
    Koller M; Schoch U; Buchmann P; Largiadèr F; von Felten A; Frick PG
    Thromb Haemost; 1986 Dec; 56(3):243-6. PubMed ID: 3551180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preliminary results of a randomized trial comparing the efficacy of standard heparin with that of fragmine, a low molecular weight heparin, in the prevention of postoperative thrombosis in cancer surgery].
    Grunebaum L; Fricker JP; Wiesel ML; Vergnes Y; Kapps J; Cazenave JP
    J Mal Vasc; 1987; 12 Suppl B():102-4. PubMed ID: 2834478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the evaluation of heparin and low molecular weight heparin in haemodialysis for chronic renal failure.
    Lane DA; Flynn A; Ireland H; Anastassiades E; Curtis JR
    Haemostasis; 1986; 16 Suppl 2():38-47. PubMed ID: 3744134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. EMRO1 (Grupo Fstudio Multicintrico RO-11).
    Moreno Gonzalez E; Fontcuberta J; de la Llama F
    Hepatogastroenterology; 1996; 43(9):744-7. PubMed ID: 8799424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.
    Holm HA; Ly B; Handeland GF; Abildgaard U; Arnesen KE; Gottschalk P; Høeg V; Aandahl M; Haugen K; Laerum F
    Haemostasis; 1986; 16 Suppl 2():30-7. PubMed ID: 3527886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biological criteria for the evaluation of prophylactic treatment with a low molecular weight heparin (Kabi 2165)].
    Le Querrec A; Derlon A; Deshayes JP; Lefrançois C; Sillard B; Delassus P; Viel JF; Kher A; Thomas M
    J Mal Vasc; 1987; 12 Suppl B():99-101. PubMed ID: 2834502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of continuous low-dose intravenous heparin administered during operation on postoperative measurements of antithrombin III and antifactor Xa.
    Jennings SA; Heather BP; Greenhalgh RM
    Surgery; 1984 Sep; 96(3):550-5. PubMed ID: 6474360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis.
    Lockner D; Bratt G; Törnebohm E; Aberg W; Granqvist S
    Haemostasis; 1986; 16 Suppl 2():25-9. PubMed ID: 3744133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of thrombosis associated with epsilon-aminocaproic acid administration and with combined epsilon-aminocaproic acid and subcutaneous heparin therapy. II. A clinical study with the aid of intravenous phlebography.
    Becker J; Borgström S; Saltzman GF
    Acta Chir Scand; 1970; 136(3):167-71. PubMed ID: 4103355
    [No Abstract]   [Full Text] [Related]  

  • 11. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis.
    Bergqvist D; Mätzsch T; Burmark US; Frisell J; Guilbaud O; Hallböök T; Horn A; Lindhagen A; Ljungnér H; Ljungström KG
    Br J Surg; 1988 Sep; 75(9):888-91. PubMed ID: 2846113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A low molecular weight heparin (KABI 2165) for prophylaxis of postoperative deep venous thrombosis.
    Onarheim H; Lund T; Heimdal A; Arnesjø B
    Acta Chir Scand; 1986 Oct; 152():593-6. PubMed ID: 3544625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options.
    Agnelli G; Caprini JA
    J Surg Oncol; 2007 Sep; 96(3):265-72. PubMed ID: 17474075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery.
    Dechavanne M; Ville D; Berruyer M; Trepo F; Dalery F; Clermont N; Lerat JL; Moyen B; Fischer LP; Kher A
    Haemostasis; 1989; 19(1):5-12. PubMed ID: 2537787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial.
    Caen JP
    Thromb Haemost; 1988 Apr; 59(2):216-20. PubMed ID: 2838923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of heparin fractions, fragments, and heparinoids.
    Messmore HL
    Semin Thromb Hemost; 1985 Apr; 11(2):208-12. PubMed ID: 2412297
    [No Abstract]   [Full Text] [Related]  

  • 17. [Low doses subcutaneously administered heparin as thrombosis prevention in surgery].
    van Vroonhoven TJ
    Ned Tijdschr Geneeskd; 1976 Jan; 120(4):159-63. PubMed ID: 1107860
    [No Abstract]   [Full Text] [Related]  

  • 18. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral anticoagulants, dextran or low-dose subcutaneous heparin: which is it to be in the prophylaxis of deep vein thrombosis of operated patients? (author's transl)].
    Verstraete M
    Przegl Lek; 1977; 34(10):777-9. PubMed ID: 594414
    [No Abstract]   [Full Text] [Related]  

  • 20. Are molecular weight and anti-Xa activity sufficient to predict the antithrombotic power of heparin fractions.
    Doutremepuich C; Bousquet F; Toulemonde F
    Thromb Res; 1986 Dec; 44(5):709-12. PubMed ID: 3810569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.